The committee reviewed several prior business items including amendments, renewals, and project closures. A new application investigating HIV infection in a humanized mouse model was discussed and granted provisional approval, contingent upon the completion of specific requirements including documentation updates, safety certification, and personnel training details. New business focused on updates regarding the NIH Draft Biosafety Policy for Research Involving Biohazards and the White House policy concerning high-risk life sciences research.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The Institutional Biosafety Committee reviewed several new applications for research involving recombinant DNA, viral vectors, and mouse models, resulting in provisional approvals contingent on meeting specific safety, training, and documentation requirements. The committee also acknowledged the review of prior business updates regarding various ongoing research applications. No new business, incident reports, or public comments were reported during the session.
May 27, 2026·BoardMeeting
Board
Rush Institutional Biosafety Committee Meeting
The committee convened to discuss the findings of a recent medical journal article documenting the first case of AAV genomic integration and oncogenesis in a human patient. As a result, the committee mandated that all principal investigators of AAV vector studies update their Informed Consent Forms to include this risk of carcinogenesis within one month, and revise other study documents such as protocols and Investigator's Brochures within three months. The Institutional Review Board will also be notified of these requirements and the affected studies.
Apr 22, 2026·BoardMeeting
Board
Rush Institutional Biosafety Committee Meeting
The committee reviewed several research applications, including the provisional approval of an AAV vector study by Dr. Bryan Killinger and the approval of two Phase III clinical studies involving CAR-T therapy led by Dr. Fotios Asimakopoulos. The session also covered updates on previous business, reviewed recent FDA news regarding gene therapy approvals, and confirmed that there were no reports concerning new business, incidents, or ongoing oversight inspections.
Extracted from official board minutes, strategic plans, and video transcripts.
